The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery

Study Overview
=================
Brief Summary
-----------------
During one-lung ventilation in patients undergoing thoracic surgery, the persistent flow in the non-ventilated lung increases intrapulmonary shunt and decreases systemic arterial oxygenation. This prospective, randomized, double blind study was conducted to evaluate the effects of inhaled iloprost during one-lung ventilation on arterial oxygenation and shunt fraction during thoracic surgery.

Official Title
-----------------
The Effect of Iloprost on Arterial Oxygenation and Shunt Fraction During One-lung Ventilation for Lung Surgery

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: Inhaled iloprost
* Drug: Distilled water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective video-assisted thoracoscopic surgery (VATS) lobectomy 20 < age < 75 American Society of Anesthesiologists (ASA) classification I III Exclusion Criteria: ASA classification IV New York Heart Association (NYHA) class III IV Severe obstructive lung disease / restrictive lung disease Pulmonary hypertension End-stage organ disease (i.e. hepatic failure, renal failure) Arrhythmia Previous history of thoracic surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Iloprost 10<br>Iloprost 10μg of inhaled iloprost (Ventavis®) Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position. | Drug: Inhaled iloprost<br>* Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.<br>|
| Experimental: Iloprost 20<br>Iloprost 20μg of inhaled iloprost (Ventavis®) Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position. | Drug: Inhaled iloprost<br>* Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.<br>|
| Placebo Comparator: Distilled water<br>Distilled water Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position. | Drug: Distilled water<br>* Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PaO2(partial pressure of arterial oxygen) | ABGA | 30 min after treatment | 
| Pulmonary shunt fraction | Qs/Qt = (CcO2-CaO2) / (CcO2-CvO2) | 30 min after treatment |